clinical trial · NCT06154902
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
Bristol-Myers Squibb·—·active not recruiting·n = 350
Multiple MyelomaIdecabtagene vicleucelNot treated
brief summary
The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.
started
Jul 29, 2022
primary completion
Jul 31, 2027
completion
Dec 31, 2027
last updated
Dec 4, 2023
official title
ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol